Antibody-Drug Conjugate Therapy One Sheet
March 23, 2023
Propel Antibody-Drug Conjugate Therapies with Clinical Trial Ready, Pathologist-Driven Assays
Antibody-drug conjugate (ADC) therapy is a proven, revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells. Good ADC therapy development decisions start with dependable research, and in the challenging, competitive pharmaceutical market, that means accurate, reliable testing protocols and results. Adopting a robust, sensitive, and specific biomarker assay alongside ADC therapy development is the key to success.